Keywords: Diagnostic, biomarker, breast cancer, TGF-beta (transforming growth factor beta), TS3SS, tumor suppressor protein, tamoxifen.
The National Cancer Institute Laboratory of Cancer Biology and Genetics, is seeking statements of capability or interest from parties interested in collaborative research to further co-develop a TGF-beta based gene signature for predicting breast cancer prognosis and response to TGF-beta antagonists.
Scientists at the National Cancer Institute have uncovered a specific gene signature that leads to differences in long-term prognoses for breast cancer. The 20-gene signature, termed TS3SS, is comprised of genes related to tumor suppressor protein Transforming Growth Factor-beta (TGF-beta). Patients with low levels of TS3SS have poorer prognoses, and patients with high levels of TS3SS have better prognoses and respond better to certain treatments, like Tamoxifen. Using this 20-gene signature as a biomarker could be a diagnostic tool for identifying high-risk patients that would benefit from more aggressive forms of treatment.
Potential Commercial Applications:
Development Stage: Pre-Clinical, in vitro and in vivo animal data available
Patent Status: U.S. Provisional Application No. 61/525,539 filed 19 Aug 2011.
Contact: Please submit an information request form at http://techtransfer.cancer.gov or contact
John Hewes, Ph.D., (301) 435-3121, firstname.lastname@example.org.
Last updated: 08/01/2012